KMT2A

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Retrieved on: 
Monday, February 26, 2024
AML, Azacitidine, Menin, KMT2A, Safety, Prognosis, FLT3, Pharmacokinetics, Venetoclax, Patient, KURA, Kura, Acute myeloid leukemia, LDAC, Cancer, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

Key Points: 
  • “Roughly half of patients with relapsed or refractory NPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is particularly poor,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Trial participants will be enrolled in one of five dose escalation cohorts, including a cohort of NPM1-mutant AML patients with a documented FLT3 co-mutation, who will be treated in combination with the FLT3 inhibitor gilteritinib.
  • Kura is conducting a series of studies to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations.
  • Preclinical data for menin inhibitors in combination with multiple FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone.

Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023: A New Generation of Proteins that have Found Application as a Therapeutic Target in Several Prevalent Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, MLL, Marketing, NPM1, Lung cancer, Protein, Indication, Acute lymphoblastic leukemia, MEN1, KMT2A, Research, FDA, EMA, Colorectal cancer, Leukemia, MYC, Diabetes, Menin, Clinical trial, Cancer, Mutation, Pancreatic cancer, Bone marrow, Patient, Acute myeloid leukemia, ALL, Acute leukemia, AML, Osteopathic medicine in Canada, Fast Track, Pharmaceutical industry

The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Menin represents a new generation of proteins that have found application as a therapeutic target in several prevalent diseases, especially cancer.
  • This has generated the need for development of menin inhibitors that can be used to treat these diseases.
  • Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 Report Highlights:
    Menin Inhibitors Drugs In Clinical Trials: > 10 Drugs
    Global Menin Inhibitors Drugs Clinical Trials By Company, Indication & Phase
    Menin Inhibitors Clinical Research Innovation Trends By Region: US, Europe & Canada

City of Hope presents pivotal clinical trial data at American Society of Hematology (ASH) conference on revumenib, a potential new targeted therapy for high-risk subtypes of acute leukemias

Retrieved on: 
Tuesday, December 12, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Eye, Food, City, Volleyball, Postcholecystectomy syndrome, ASH, Disease, Haematopoietic system, Clinical trial, Patient, Multimedia, Bakersfield College, Viral, Division, FDA, CRH, KMT2A, Hematology, Blood, ORR, Nausea, Cancer, Survival, Chronic pain, AML, Family, ALL, Bone marrow, Travel, Acute leukemia, Pharmaceutical industry, Leukemia, Hope

The data was presented as a late-breaking abstrac t at ASH and in a press briefing.

Key Points: 
  • The data was presented as a late-breaking abstrac t at ASH and in a press briefing.
  • View the full release here: https://www.businesswire.com/news/home/20231212429407/en/
    City of Hope's Ibrahim Aldoss, M.D., presented the research at ASH conference.
  • Tatum Demontmorency , 19, participated in the clinical trial at City of Hope after she was diagnosed with leukemia in 2021.
  • If approved for use by the FDA, the product would be the first therapy to target what’s known as the menin-KMT2A interaction.

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

Bionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research

Retrieved on: 
Wednesday, April 26, 2023
CLL, Myelodysplastic syndrome, FISH, University, CDK6, TP53, Chronic lymphocytic leukemia, ALL, Acute lymphoblastic leukemia, Genomics, Bone marrow, SVS, KMT2A, Doctor of Philosophy, VAF, SV, Teaching hospital, Acute myeloid leukemia, Ruhr University Bochum, MDS, AML, Publication, SAN, In situ hybridization, Cytogenetics, OGM, University of Oulu, Vaccine, Microscope, TCL1A

The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.

Key Points: 
  • The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.
  • The authors also noted OGM’s ability to detect currently unknown variants, which might give insight into disease biology and refine risk stratification.
  • evaluated the performance of OGM against traditional cytogenetic methods in 29 samples characterized as AML or ALL.
  • is one of the first studies to evaluate the utility of OGM in chronic lymphocytic leukemia (CLL) samples.

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Mixed-phenotype acute leukemia, Neoplasm, Incidence, Security (finance), KURA, DNMT3A, Acute leukemia, ASH, FLT3, AML, QT interval, Toxicity, Research, Food, FDA, Safety, Cancer, Bone marrow, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRD, Duke Cancer Institute, IDH, Society, FTI, Therapy, Breakthrough therapy, CRH, KMT2D, News, HRAS, Venetoclax, Element, Disease, Patient, DS, NPM1, CT, Prognosis, Optimus, CR, Survival, Orphan, IND, HNSCC, Risk, Postcholecystectomy syndrome, Pharmaceutical industry, KMT2A

SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML).

Key Points: 
  • These data are being featured during an oral session today at the American Society of Hematology (ASH) Annual Meeting.
  • The patient entered the trial having progressed through seven prior lines of therapy and remains on ziftomenib after two years.
  • ET today, December 10, 2022, following the oral presentation of updated data from the KOMET-001 clinical trial at the ASH Annual Meeting in New Orleans.
  • Ziftomenib, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged AML.

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
MLL, Fast Track, KMT2A, Menin, Webcast, Food, Phenotype, Breakthrough therapy, Orphan, Patient, CR, OS, ALL, FDA, Mixed-phenotype acute leukemia, DOR, Acute lymphoblastic leukemia, CYP3A4, Acute leukemia, COVID-19, AML, Growth, Safety, Risk, Acute myeloid leukemia, Pharmacokinetics, NPM1, Mutation, Pharmaceutical industry

WALTHAM, Mass., Dec. 10, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A rearranged (KMT2r) relapsed/refractory (R/R) acute myeloid or acute lymphoid leukemias (ALL or AML). Revumenib is the Company's highly selective, oral menin inhibitor. The data were featured during two oral sessions today at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Revumenib is currently being evaluated in several clinical trials, including the Company's pivotal AUGMENT-101 Phase 1/2 open-label clinical trial for the treatment of relapsed/refractory (R/R) acute leukemias.
  • Revumenib was also granted Breakthrough Therapy Designation by the FDA for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement.
  • AUGMENT-101 is a Phase 1/2 open-label trial designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of orally administered revumenib.
  • Patients will be enrolled across each of the following trial populations: patients with NPM1 mutant AML, patients with KMT2Ar (MLLr) AML, and patients with KMT2Ar (MLLr) ALL.

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Prognosis, HNSCC, Company, Research, Therapy, 2021 Essex County Council election, SAN, Society, Drug resistance, Cancer, GLOBE, Breakthrough therapy, EGFR, Safety, KMT2A, IND, NSCLC, Neoplasm, ASH, Biomarker, FTI, Acute myeloid leukemia, Nasdaq, Transplant, Session, HRAS, U.S. Securities and Exchange Commission, Acute lymphoblastic leukemia, Tipifarnib, Pharmacology, Risk, KURA, Security (finance), News, SEC, AML, NPM1, Patient, Program, Cellular, Pharmaceutical industry, Dentistry, Diagnosis

We are honored that several abstracts showcasing our menin inhibitor program have been selected for presentation, including an oral presentation of updated data from our KOMET-001 trial of ziftomenib in relapsed/refractory acute myeloid leukemia, said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.

Key Points: 
  • We are honored that several abstracts showcasing our menin inhibitor program have been selected for presentation, including an oral presentation of updated data from our KOMET-001 trial of ziftomenib in relapsed/refractory acute myeloid leukemia, said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Session titles and information for the four abstracts are listed below and are now available on the ASH online itinerary planner.
  • Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
    Copies of the presentations will be available on Kura's website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

Kura Oncology Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Bristol Myers Squibb, Society, FDA, Large-cell lung carcinoma, Research, National Institute, U.S. Securities and Exchange Commission, INSERM, Program, Company, GLOBE, KMT2A, IND, Breakthrough, Mutation, ASH, FTI, HRAS, Tipifarnib, ID, Security (finance), NPM1, Patient, Cancer, HNSCC, Breakthrough therapy, EGFR, Webcast, Neoplasm, Medicine, Head, Data, KURA, Therapy, III, Investment, Safety, NSCLC, Nasdaq, Organization, PIK3CA, Risk, News, AML, Achievement, EORTC, Bank, Pharmaceutical industry, Lithium

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2022 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2022 were $25.0 million, compared to $22.4 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $11.6 million, compared to $11.3 million for the third quarter of 2021.
  • ET / 5:00 a.m. PT today, November 3, 2022, to discuss the financial results for the third quarter 2022 and to provide a corporate update.